CompletedPhase 2NCT01068769

Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

Studying Gastrointestinal stromal tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Suzanne George, MD
Principal Investigator
Suzanne George, MD
Dana-Farber Cancer Institute
Intervention
regorafenib(drug)
Enrollment
34 target
Eligibility
18 years · All sexes
Timeline
20102020

Study locations (4)

Collaborators

Brigham and Women's Hospital · Massachusetts General Hospital · Fox Chase Cancer Center · Oregon Health and Science University · Bayer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01068769 on ClinicalTrials.gov

Other trials for Gastrointestinal stromal tumor

Additional recruiting or active studies for the same condition.

See all trials for Gastrointestinal stromal tumor

← Back to all trials